Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

NCT04799847 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

161

Enrollment

INDUSTRY

Sponsor class

Conditions

Bladder Cancer

Interventions

DRUG: Catumaxomab

Sponsor

LintonPharm Co.,Ltd.